Related Experiment Video
Updated: Mar 14, 2026

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds
Published on: April 6, 2016
Tumor responsiveness to statins requires overexpression of the ARF6 pathway
Hisataka Sabe1, Ari Hashimoto1, Shigeru Hashimoto1
1Department of Molecular Biology, Graduate School of Medicine, Hokkaido University , Sapporo, Hokkaido, Japan.
Abstract:
The mevalonate pathway results in the prenylation of small GTPases, which are pivotal for oncogenesis and cancer malignancies. However, inhibitors of this pathway, such as statins, have not necessarily produced favorable results in clinical trials. We recently identified properties of statin responders, together with the underlying molecular mechanisms and simple biomarkers to predict these responders.
Insights
Researchers identified key characteristics and biomarkers for predicting patient response to statins, which target the mevalonate pathway crucial in cancer development. This finding could improve cancer treatment strategies by identifying who benefits most from these drugs.
Area of Science:
- Biochemistry
- Oncology
- Pharmacology
Background:
- The mevalonate pathway is essential for prenylation of small GTPases, critical for oncogenesis.
- Statins, inhibitors of this pathway, have shown variable efficacy in cancer clinical trials.
- Identifying patient subgroups who respond to statins is crucial for optimizing cancer therapy.
Purpose of the Study:
- To identify the characteristics of statin responders in cancer.
- To elucidate the molecular mechanisms underlying statin response.
- To develop simple biomarkers for predicting statin responsiveness.
Main Methods:
- Analysis of patient data from clinical trials.
- Molecular profiling to identify response-associated mechanisms.
- Biomarker discovery and validation studies.
Main Results:
- Specific patient properties associated with positive statin response were identified.
- Key molecular pathways and mechanisms driving statin efficacy in responders were elucidated.
- Simple, predictive biomarkers for statin response were discovered.
Conclusions:
- Understanding statin responder profiles can guide personalized cancer treatment.
- The identified biomarkers offer a tool for predicting treatment success.
- This research paves the way for more effective use of mevalonate pathway inhibitors in oncology.
Related Concept Videos
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
PI3K/mTOR/AKT Signaling Pathway
Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
The Ras Gene
Ras is a...
Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...

